AstraZeneca withdraws Imfinzi indication in advanced bladder cancer

AstraZeneca said it has voluntarily withdrawn the U.S. FDA’s accelerated approval for immunotherapy Imfinzi (ingredient: durvalumab) after failing to prove its efficacy in the phase-3 study.The withdr [전체본문 2021-02-23 13:49:00Z]